Novo Nordisk Analyst Ratings
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $160
Don't Forget This Startup's Weight-Loss Pill, Analyst Says -- Barrons.com
Why Eli Lilly Is a Buy After Earnings. The Stock Got an Upgrade. -- Barrons.com
Eli Lilly & Co (LLY) Buy Rating Affirmed on Strong HFpEF Data and Competitive Edge Over Novo Nordisk (NVO)
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
Novo Nordisk (0QIU) Receives a Buy From J.P. Morgan
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings
Novo Nordisk Analyst Ratings